Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56–57

HOS-109016 · Präparat HOS-093083

56 Benzodiazepines Midazolam Oral Midazolam: Kaletra must not be co-administered AUC: ↑ 13-fold with oral midazolam (see section Parenteral Midazolam: 4.3), whereas caution should be used AUC: ↑ 4-fold with co-administration of Kaletra and Due to CYP3A inhibition by parenteral midazolam. If Kaletra is lopinavir/ritonavir co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam should be considered especially if more than a single dose of midazolam is administered. Beta2-adrenoceptor agonist (long acting) Salmeterol Salmeterol: The combination may result in Concentrations are expected to increased risk of cardiovascular increase due to CYP3A inhibition adverse events associated with by lopinavir/ritonavir. salmeterol, including QT prolongation, palpitations and sinus tachycardia. Therefore, concomitant administration of Kaletra with salmeterol is not recommended (see section 4.4). Calcium channel blockers Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic and Nicardipine Nicardipine: and adverse effects is recommended Concentrations may be increased when these medicines are due to CYP3A inhibition by concomitantly administered with lopinavir/ritonavir. Kaletra. Corticosteroids Dexamethasone Lopinavir: Clinical monitoring of antiviral Concentrations may be decreased efficacy is recommended when these due to CYP3A induction by medicines are concomitantly dexamethasone. administered with Kaletra.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage bbdb1518d507ab9bf3037f812d7ca4e3f06d2a449a3a956237657f28f1c80c69 · Zeichen 40688–43969 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.